1
/
of
1
British Medical Association,Royal Pharmaceutical Society of Great Britain
British national formulary: 84: September 2022 - March 2023
British national formulary: 84: September 2022 - March 2023
YOU SAVE £2.11
Regular price
£63.84 GBP
Regular price
£65.95 GBP
Sale price
£63.84 GBP
Unit price
/
per
Tax included.
Shipping calculated at checkout.
- Condition: Brand new
- UK Delivery times: Usually arrives within 2 - 3 working days
- UK Shipping: Fee starts at £2.39. Subject to product weight & dimension
Low Stock: Only 1 copies remaining
Couldn't load pickup availability
- More about British national formulary: 84: September 2022 - March 2023
The British Pharmacopoeia is the official book of the British Pharmacopoeia Commission and is used by healthcare professionals in the UK. It contains information on over 1,000 drugs and provides guidance on their use, composition, and quality.
The British Pharmacopoeia is the official book of the British Pharmacopoeia Commission and is used by healthcare professionals in the UK. It contains information on over 1,000 drugs and provides guidance on their use, composition, and quality.
Format: Paperback / softback
Length: 1880 pages
Publication date: 14 September 2022
Publisher: Pharmaceutical Press
The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.
The new edition (BNF 84) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines.
Extensive content updates in the BNF 84 edition include:
New monographs for:
- Aspaveli® [pegcetacoplan] for paroxysmal nocturnal haemoglobinuria
- Givlaari® [givosiran] for acute hepatic porphyria
- Jemperli® [dostarlimab] for endometrial cancer
- Paxlovid® [nirmatrelvir with ritonavir] for COVID-19
- Shingrix® [herpes-zoster vaccine (recombinant, adjuvanted)] for immunisation against herpes zoster (shingles)
- Vazkepa® [icosapent ethyl] as an adjunct to statin in prevention of cardiovascular events in hyperlipidaemia
- Vumerity® [diroximel fumarate] for multiple sclerosis
- Xevudy® [sotrovimab] for COVID-19
- Xofluza® [baloxavir marboxil] for post-exposure prophylaxis or treatment of influenza
MHRA advice on:
- Amiodarone hydrochloride (Cordarone X®): reminder of risks of treatment and need for patient monitoring and supervision
- Brolucizumab (Beovu®): updated recommendations to minimise the known risk of intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion
- Chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- Cladribine (Mavenclad®): new advice to minimise risk of serious liver injury
- COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- Haloperidol (Haldol®): reminder of risks when used in elderly patients for the acute treatment of delirium
- Hydroxychloroquine sulfate: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- Ivacaftor, tezacaftor, elexacaftor (Kaftrio®▼) in combination with ivacaftor (Kalydeco®): risk of serious liver injury; updated advice on liver function testing
- Metformin hydrochloride: study shows no safety concerns in pregnancy
- Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
- Pregabalin (Lyrica®): findings of safety study on risks during pregnancy
- Venetoclax (Venclyxto®): updated recommendations on tumour lysis syndrome
Other significant changes include updated guidance on:
- Antiplatelet drugs for transcatheter aortic valve implantation
- Buprenorphine transdermal patch strengths and prescribing considerations
- Maximum daily doses added for colecalciferol and ergocalciferol in the treatment of vitamin D deficiency
- COVID-19 updated guidance in-line with UK Health Security Agency recommendations
- Management of acute otitis media
- New requirement to register patients onto Esketamine (Spravato®) Register and Alert system
- Management of glaucoma and ocular hypertension
- Immunisation schedule updated guidance in-line with Public Health England/UK Health Security Agency recommendations, including human papillomavirus, influenza, and varicella-zoster vaccines
- Individual monographs created for herpes-zoster vaccine (recombinant, adjuvanted), herpes-zoster vaccine, live, and varicella-zoster vaccine
- Miconazole oral gel no longer licensed for treatment of intestinal candidiasis
- Obstetrics: induction of labour
- Phosphate imbalance
- Potassium permanganate: inadvertent oral administration of potassium permanganate [National Patient Safety Alert advice]
- Sex hormones: use of progestogens for the prevention of miscarriage
- Smoking cessation
BNF 84 is an essential publication, it provides you with:
• Up-to-date information on prescribing, dispensing, and administering medicines
• Authoritative, independent guidance on best practice enabling you to select safe and effective medicines
• Information you know you can trust for quality, reliability, and independence
• Everything you need at your fingertips, all in one book
Dimension: 210 (mm)
ISBN-13: 9780857114327
Edition number: 84th ed
This item can be found in:
UK and International shipping information
UK and International shipping information
UK Delivery and returns information:
- Delivery within 2 - 3 days when ordering in the UK.
- Shipping fee for UK customers from £2.39. Fully tracked shipping service available.
- Returns policy: Return within 30 days of receipt for full refund.
International deliveries:
Shulph Ink now ships to Australia, Canada, France, Ireland, Italy, Germany, Spain, Netherlands, New Zealand, United States of America, Belgium, India, United Arab Emirates.
- Delivery times: within 5 - 10 days for international orders.
- Shipping fee: charges vary for overseas orders. Only tracked services are available for international orders.
- Customs charges: If ordering to addresses outside the United Kingdom, you may or may not incur additional customs and duties fees during local delivery.
![British national formulary: 84: September 2022 - March 2023](http://shulphink.com/cdn/shop/products/image_ee9a98f1-1311-410a-b7df-f3e461977da4.jpg?v=1672147150&width=1445)